DexCom (DXCM) shares rallied 5.6% in the last trading session to close at $80.04. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.8% gain over the past four weeks.The sharp upsurge in Dexcom's shares can be attributed to the Novo Nordisk's announcement that its next-generation weight-loss drug, CagriSema, did not meet the high expectations in a key study, achieving a 22.7% weight loss instead of the anticip ...